Hemostemix recently declared the incorporation of PreCerv inc . (A totally closely-held subsidiary of Hemostemix). Hemostemix can grant PreCerv a world field of use licence for NCP-01 and its autologous somatic cell technology to treat central and peripheral systema nervosum diseases.
Hemostemix recently granted the global field license of use of NCP-01 and its autologous stem cell therapies to PreCerv Inc. its wholly owned subsidiary to aid patients with peripheral and central nervous system conditions
Hemostemix Inc. announced that it will pay interest of $84,804.40 by issuing 446,339 Common Shares, using the March 2, 2022 closing price of $0.19 per share, to the convertible debenture holder in satisfaction of interest due on the outstanding principal amount of $2,500,000 for the period from inception, June 11, 2021, to December 31, 2021.
The perpetual lawsuit held between hemostenix and aspire health science has met its end, eventually enabling the company to gain back ultimate possession over its lost intellectual property.
Hemostemix has announced that it has closed the previously released non-brokered convertible debenture in accordance with offering $1,000 principal amount of each debenture.
As the court ruled in the favor of Hemostemix and all the intellectual property relating to ACP-01 was returned to Hemostemix, the management is independent to cultivate important business development strategies as well as it enables the extraction of phase 2 clinical trial data.
For settling all the financial transactions of the company, Hemostemix has appointed a special advisor, Mr. Richard Groome, to the CEO, who believes that he’s a great addition to the team.
Hemostemix (TSXV: $HEM) primarily deals with developing and commercializing innovative blood-derived stem cell therapies. Is now entered into an agreement with Aspire and has agreed to settle the dispute of data stealth and intellectual property infringement regarding ACP-01.
In connection with the previous agreement dispute, Hemostemix has recently announced the closure of the agreement and the settlement of all prosecution with Aspire Health Science in a very recent news release by the company itself.
In the very recent news release, the company announces that it possesses the entirety of its intellectual property, including all HS 12-01 Phase II clinical path information and all authentic information from Hemostemix Israel.
Hemostemix Inc. is a biotech company situated in Calgary, Canada, headed by Thomas A. Smeenk. The company manages the exploration, improvement, and assembling of inventive blood-derived stem cell therapies with marvelous recuperating and recovery properties bringing about less immunogenic variables.
The company’s lead candidate for phase II clinical-stage trial is doing wonders in medication, helping patients experiencing ulcers and CLI or other ischemic issues like peripheral artery disease and keeping the patients from getting their limb amputated.
@Hemostemix has filed and owns 91 patents in more than 25 jurisdictions covering 5 different categories, and has also won world economic forum technology pioneer award with several peer reviewed articles published.
Hemostemix $HEM has finished the detailed information review to guarantee the authenticity. The company has affirmed that the materials held by Aspire are finished and liberated from manipulation.
Hemostemix Inc. (TSXV: HEM) is a biotechnology company occupied with the innovative work and the assembling and commercializing of blood-determined stem cell therapies. Shares outstanding of all classes are 67M, assessing the stocks for 52-weeks are viewed as 0.39 (high) and 0.13 (low).
Hemostemix refreshed another release concerning the end of a non-brokered convertible debenture. The chief sum is convertible at the choice of the debenture holder into a common share of the company at the cost of $0.175 per normal offering.
$HMTXF OTC:HMTXF observed a sudden spike after announcing the closure of its $2.75 Million worth of non-brokered private placement of convertible debentures unit offering
Hemostemix Inc. ( TSXV: $HEM ) is an innovative-driven publicly-traded biotech company. Its principal business is developing, manufacturing, and commercializing innovative blood-derived stem cell therapies. The company is currently offering a trading volume of 130K+, followed by the 30-day estimated average volume of 240.6K. TSXV:HEM